.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Levodopa remains the most effective symptomatic treatment for Parkinson disease, but clinicians have long debated whether starting it early accelerates later motor complications or changes disease progression. The LEAP delayed-start trial followed patients with early Parkinson disease who were assigned to start levodopa immediately or after a 40-week delay. Follow-up showed that starting levodopa earlier improved symptoms of bradykinesia, rigidity and tremor during active treatment, but the delayed-start design did not demonstrate a durable disease-modifying advantage attributable to earlier initiation. Later analyses also found that early initiation was not associated with more motor fluctuations at 80 weeks. The practical message is therefore reassuring: clinicians do not need to delay levodopa solely because of fear that starting treatment early will worsen the long-term course. Treatment timing should be based on symptom burden, functional impact, patient priorities and the need to maintain quality of life. The study supports a patient-centred approach to levodopa initiation rather than rigid rules about waiting until disability becomes substantial.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Levodopa remains the most effective symptomatic treatment for Parkinson disease, but clinicians have long debated whether starting it early accelerates later motor complications or changes disease progression. The LEAP delayed-start trial followed patients with early Parkinson disease who were assigned to start levodopa immediately or after a 40-week delay. Follow-up showed that starting levodopa earlier improved symptoms of bradykinesia, rigidity and tremor during active treatment, but the delayed-start design did not demonstrate a durable disease-modifying advantage attributable to earlier initiation. Later analyses also found that early initiation was not associated with more motor fluctuations at 80 weeks. The practical message is therefore reassuring: clinicians do not need to delay levodopa solely because of fear that starting treatment early will worsen the long-term course. Treatment timing should be based on symptom burden, functional impact, patient priorities and the need to maintain quality of life. The study supports a patient-centred approach to levodopa initiation rather than rigid rules about waiting until disability becomes substantial.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
